ResearcherHubei University of Chinese MedicineNo recent work listed

Tianzhu Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4439-4334; OpenAlex author ID A5100648979. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

Sustained delivery of gemcitabine via in situ injectable mussel-inspired hydrogels for the local therapy of pancreatic cancer. Last author DOI 10.1039/d1tb02858h ↗
MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5. Co-author DOI 10.1093/carcin/bgz121 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jian He · 1 shared paper, 2022 · strength 0.15
- Paper Sustained delivery of gemcitabine via in situ injectable mussel-inspired hydrogels for the local therapy of pancreatic … DOI 10.1039/d1tb02858h ↗
Li Xu · 1 shared paper, 2022 · strength 0.15
- Paper Sustained delivery of gemcitabine via in situ injectable mussel-inspired hydrogels for the local therapy of pancreatic … DOI 10.1039/d1tb02858h ↗
Zhongxin Lu · 1 shared paper, 2020 · strength 0.11
- Paper MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting S… DOI 10.1093/carcin/bgz121 ↗
Hui Hu · 1 shared paper, 2020 · strength 0.11
- Paper MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting S… DOI 10.1093/carcin/bgz121 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.